charles reinhart  pacira pharmaceuticals inc  zoominfocom insider trading  reinhart charles a iii  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  reinhart charles a iii select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing option award  pm na pacira pharmaceuticals inc pcrx reinhart charles a iiichief financial officer   direct view option award  pm na pacira pharmaceuticals inc pcrx reinhart charles a iiichief financial officer   direct view   secformcom all rights reserved archives        fri  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement  charles a reinhart iii executive profile  biography  bloomberg july    am et pharmaceuticals company overview of pacira pharmaceuticals inc snapshotpeople  overviewboard memberscommittees executive profile charles a reinhart iiichief financial officer pacira pharmaceuticals incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriesas of fiscal year  background mr charles a reinhart iii also known as charlie has been chief financial officer at pacira pharmaceuticals inc since may   mr reinhart is responsible for overseeing all financial and capital market activities at pacira including accounting financial reporting financial planning and analysis and investor relations prior to joining pacira he served as chief financial officer of covis pharmaceuticals inc he served as chief financial officer and executive  vice president at archimedes pharma limited since september  he joined archimedes pharma in september  mr reinhart served as chief financial officer and senior vice president at pharmathene inc from august   to september   and had oversees its accounting and finance functions human resources and information technology prior to pharmathene mr reinhart served as senior vice president of finance and corporate strategy and a member of the operating leadership team of millennium pharmaceuticals inc where he was responsible for all aspects of its finance and strategic sourcing functions he has  years of diversified experience in executive management strategic planning debt and equity financing investor relations business development accounting and financial reporting tax treasury financial planning and analysis and risk management mr reinhart has successfully built and managed finance organizations within rapidly growing companies responsible for accounting and financial reporting financial planning and analysis tax treasury risk management and procurement he has worked closely with commercial teams to evaluate sales operations monitor product pricing and implement contracting strategies in addition he has significant experience in investor relations corporate development and capital raising he has been integrally involved in equity and debt financing transactions as well as the evaluation acquisition and integration of multiple products and companies mr reinhart served as vice president of finance at cephalon inc where he was responsible for worldwide accounting financial reporting sarbanes oxley compliance tax treasury and budgetingforecasting functions he served as chief financial officer vice president and treasurer of delsys pharmaceutical corporation prior to joining delsys mr reinhart worked as the director of finance and administration at genvec inc he served as chief financial officer for dynamic digital displays he held various positions for ernst  whinney now ernst  young including manager in the audit department he serves as a director of vectorlogics inc mr reinhart is a certified public accountant he earned his masters of business administration from the wharton school at the university of pennsylvania and earned his bachelor of science degree in business and economics from lehigh universityread full background corporate headquarters  sylvan wayparsippany new jersey united statesphone fax  board members memberships there is no board members memberships data available education bs lehigh universitymba university of pennsylvania  the wharton school other affiliations delsys pharmaceutical corporationlehigh universityuniversity of pennsylvania  the wharton schoolpharmathene incarchimedes pharma limited annual compensation salarybonustotal annual compensation stocks options all other compensationunexercisable optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationrajat rai chief executive officerakorn incklars marcher chief executive officer president and member of executive boardambu asa j kazimi mbafounder chairman chief executive officer and presidentcumberland pharmaceuticals inckleon o moulder jr mbacofounder chief executive officer and directortesaro inckjoseph f woody ceo  directorhalyard health inccompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact pacira pharmaceuticals inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close pacira pharmaceuticals appoints charles a reinhart iii as chief financial officer  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street pacira pharmaceuticals appoints charles a reinhart iii as chief financial officer globenewswire apr    am edt parsippany nj april   globe newswire  pacira pharmaceuticals inc nasdaqpcrx today announced the appointment of charles a reinhart iii to the position of chief financial officer mr reinhart will be responsible for overseeing all financial and capital market activities at pacira including accounting financial reporting financial planning and analysis and investor relations in this position he will succeed former chief financial officer jim scibetta who is currently president and will report to dave stack chief executive officer and chairman mr reinhart will start in this new role effective tuesday may   we are excited to welcome another key member to our leadership team in order to properly resource our growing pacira brand said mr stack charlie brings valuable experience from working at commercial stage biotech and specialty pharmaceutical companies succeeding in roles that both meet and exceed traditional cfo responsibilities—the type of strategic background and expertise that will help support the successful expansion of exparel® bupivacaine liposome injectable suspension and pipeline opportunities prior to joining pacira mr reinhart served as chief financial officer of covis pharmaceuticals inc archimedes pharma ltd and pharmathene inc he has also held senior financial roles at millennium pharmaceuticals inc cephalon inc and several early stage life sciences companies mr reinhart has successfully built and managed finance organizations within rapidly growing companies responsible for accounting and financial reporting financial planning and analysis tax treasury risk management and procurement he has worked closely with commercial teams to evaluate sales operations monitor product pricing and implement contracting strategies in addition he has significant experience in investor relations corporate development and capital raising he has been integrally involved in equity and debt financing transactions as well as the evaluation acquisition and integration of multiple products and companies mr reinhart earned his bachelor of science degree from lehigh university and his mba from the wharton school of the university of pennsylvania he is also a cpa if you liked this article you might like biotech premarket movers editas amphastar aratana pacira editas medicine amphastar pharmaceuticals aratana therapeutics and pacira pharmaceuticals were among the biotech stock movers in premarket trading on tuesday armie margaret lee mar    am edt pacira pharmaceuticals tops q earnings expectations pacira pcrx reported mixed fourth quarter results tony owusu mar    am est biotech premarket movers pacira clearside biomedical and organovo pacira pharmaceuticals clearside biomedical and organovo holdings are among the premarket biotech movers on wednesday armie margaret lee jan    am est bullish and bearish reversals in the market these companies show signs of a change of direction guy ortmann jan    pm est trending i believe ugly would be the proper term for the selloff market recon starbucks shares are crashing go out and buy amazon falls obamacare repeal fails   things you must know before the market opens dont buy the hype twitter isnt dead yet att verizon prove their worth stock futures lower on amazons earnings disappointment us economy grows  in q advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers pacira pharmaceuticals appoints charles a reinhart iii as chief financial officer  pg  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street pacira pharmaceuticals appoints charles a reinhart iii as chief financial officer globenewswire apr    am edt i am pleased to join pacira during this period of investment and growth and look forward to leading the talented finance team that jim scibetta has already assembled here said mr reinhart by providing an effective nonopioid option like exparel for the treatment of postsurgical pain pacira has been able to demonstrate improved patient outcomes and lower overall costs to the healthcare system i am excited to build upon the success of this product as well as the companys future opportunities in my shared commitment with pacira to enhance the patient experience and drive shareholder value about pacira                                                                            pacira pharmaceuticals inc nasdaqpcrx is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients the companys flagship product exparel® bupivacaine liposome injectable suspension indicated for singledose infiltration into the surgical site to produce postsurgical analgesia was commercially launched in the united states in april  exparel and two other products have successfully utilized depofoam® a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time additional information about pacira is available at wwwpaciracom about exparel® exparel bupivacaine liposome injectable suspension is currently indicated for singledose infiltration into the surgical site to produce postsurgical analgesia the product combines bupivacaine with depofoam® a proven product delivery technology that delivers medication over a desired time period exparel represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri or postsurgical setting by utilizing the depofoam platform a single dose of exparel delivers bupivacaine over time providing significant reductions in cumulative pain score with up to a  percent decrease in opioid consumption the clinical benefit of the opioid reduction was not demonstrated additional information is available at wwwexparelcom    forward looking statements any statements in this press release about our future expectations plans outlook and prospects and other statements containing the words believes anticipates plans estimates expects intends may and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including risks relating to the success of our sales and manufacturing efforts in support of the commercialization of exparel the rate and degree of market acceptance of exparel the size and growth of the potential markets for exparel and our ability to serve those markets our plans to expand the use of exparel to additional indications and opportunities and the timing and success of any related clinical trials the related timing and success of united states food and drug administration supplemental new drug applications the outcome of the us department of justice inquiry our plans to evaluate develop and pursue additional depofoambased product candidates clinical studies in support of an existing or potential depofoambased product our plans to continue to manufacture and provide support services for our commercial partners who have licensed depocyte our commercialization and marketing capabilities our and patheon uk limiteds ability to successfully and timely construct dedicated exparel manufacturing suites and other factors discussed in the risk factors of our most recent annual report on form k for the fiscal year ended december   and in other filings that we periodically make with the sec in addition the forwardlooking statements included in this press release represent our views as of the date of this press release important factors could cause our actual results to differ materially from those indicated or implied by forwardlooking statements and as such we anticipate that subsequent events and developments will cause our views to change however while we may elect to update these forwardlooking statements at some point in the future we specifically disclaim any obligation to do so these forwardlooking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release company contactpacira pharmaceuticals incjessica cho  jessicachopaciracommedia contactcoyne public relationsalyssa schneider  aschneidercoyneprcom if you liked this article you might like biotech premarket movers editas amphastar aratana pacira editas medicine amphastar pharmaceuticals aratana therapeutics and pacira pharmaceuticals were among the biotech stock movers in premarket trading on tuesday armie margaret lee mar    am edt pacira pharmaceuticals tops q earnings expectations pacira pcrx reported mixed fourth quarter results tony owusu mar    am est biotech premarket movers pacira clearside biomedical and organovo pacira pharmaceuticals clearside biomedical and organovo holdings are among the premarket biotech movers on wednesday armie margaret lee jan    am est bullish and bearish reversals in the market these companies show signs of a change of direction guy ortmann jan    pm est trending amazon falls obamacare repeal fails   things you must know before the market opens i believe ugly would be the proper term for the selloff market recon starbucks shares are crashing go out and buy dont buy the hype twitter isnt dead yet att verizon prove their worth stock futures lower on amazons earnings disappointment us economy grows  in q advertising partners  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers a reinhart charles iii  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors a reinhart charles iii check out list of companies and businesses related to a reinhart charles iii find out a reinhart charles iii address and contact details view other people related to a reinhart charles iii  coworkers colleagues companions etc address co pharmathene inc one park place suite  annapolis  md companies related to a reinhart charles iii cikcompany namepositioncompany addressaltimmune inc firstfield road gaithersburg  a reinhart charles iii on the web persons related to a reinhart charles iii  altimmune incnamepositioncityeric aguiarprincetonedward b bergerdes moinesedward b bergertucsonchristopher c camutvp govt contracts annapolisjames h cavanaughdirector princetonlinda l changsvp cfo  secretary annapolislinda l changsvp cfo  secretary annapolisreinhart charles iiiannapoliscamut christopherannapolisfrancesca m cooksvp policy  govt affairs annapolisfrancesca m cooksvp policy  govt affairs annapolisfrancesca m cooksvp policy  govt affairs annapoliselizabeth czerepaksee remarks germantownelizabeth czerepakdirector new yorkwright davidannapolisschaffer deraceannapolisschaffer deraceannapolisdavid drutzdirector raleighisrael a englandernew yorkwilliam enrightsee remarks gaithersburgrichman ericannapolisrichman ericannapoliscook francescaannapoliscook francescaannapolisphil frohlichtulsaphil frohlichtulsaphil frohlichtulsaphil frohlichtulsathomas richard fuerstevp chief scientific officer annapolisjoan fuscosvp operations annapolisjoan fuscosvp operations annapolisansbert gadickebostonnicholas galakatosbostonjohn gilldirector annapolisjohn gilldirector annapolisjohn gilldirector annapolisjohn gilldirector annapolishealthcare partners vii lpprincetonhealthcare partners vii lpprincetonhealthcare ventures vii lp owner princetonhealthcare ventures vii lp owner princetondennis hennerbostonphilip hodgesdirector gaithersburgcavanaugh jamesannapoliscavanaugh jamesannapolisrunge jeffreyannapolisfusco joanannapolisfusco joanannapolismccleary joelannapolismccleary joelannapolisgill johnannapolisgill johnannapolispappajohn johnannapolispappajohn johnannapolisjeffrey michael jonescoo annapoliskarp jordanannapoliskarp jordanannapolisjordan p karpsvp general counsel annapolisjordan p karpsvp general counsel annapolisjordan p karpsvp general counsel annapolismatthew p kinleydes moinesmatthew p kinleypresident  treasurer des moinesmatthew p kinleypresident  treasurer des moinesmatthew p kinleypresident  treasurer des moinesmatthew p kinleypresident and treasurer des moinesaugustine lawlorcambridgejohn w littlechildcambridgephilip macneillvp cfo treasurer secretary annapolisbrian a markisondirector annapolisbrian a markisondirector annapolisbrian a markisondirector annapolisjoel mcclearydirector annapolisjoel mcclearydirector annapolisjoel mcclearydirector annapolismillennium management llcnew yorkchristopher mirabellicambridgesayare mitchelannapoliswayne morgesvp regulatory affairs  qual annapoliswayne morgesvp regulatory affairs  qual annapoliswayne morgessvp reg affairs  quality annapolismpm asset management investors  bviii llcbostonmpm bioventures iii gmbh  co beteiligungs kgbostonmpm bioventures iii gp lpbostonmpm bioventures iii gp lpbostonmpm bioventures iii lpbostonmpm bioventures iii llc owner bostonmpm bioventures iii lpbostonmpm bioventures iii parallel fund lpbostonmpm bioventures iii parallel fund lpbostonmpm bioventures iiiqp lpbostonmpm bioventures iii qp lpbostonag novartisch baselnovartis bioventures ltdhamiltonjohn pappajohnchairman and secretary des moinesjohn pappajohndirector annapolisjohn pappajohndirector annapolisjohn pappajohndirector annapolisjohn pappajohndes moinesjohn pappajohnchairman and secretary des moinesjohn pappajohnchairman and secretary des moinesjohn pappajohnchairman and secretary des moinesparadigm venture partners lpgaithersburgprescott group capital management llctulsaprescott group capital management llctulsaprescott group capital management llc owner tulsakevin pricepresidentpharmathene uk ltd billinghamkevin pricepresident  pharmathene ukltd billinghamredmont vaxn capital holdings llcgaithersburgredmont venture partners incgaithersburgcharles a reinhart iiiannapolischarles a reinhart iiisvp chief financial officer annapolischarles a reinhart iiisvp chief financial officer annapoliseric i richmandirector new yorkeric i richmansee remarks annapoliseric i richmansee remarks annapoliseric i richmanpresident and ceo annapolisvalerie d riddlesvp medical director annapolism scot robertschief scientific officer gaithersburgjeffrey w rungedirector annapolisjeffrey w rungedirector annapolisjeffrey w rungedirector annapolismitchel sayaredirector cambridgemitchel sayareannapolisklaus schaferdirector gaithersburgderace l schafferdirector rochesterderace l schaffervice chairman and ceo des moinesderace l schaffervice chairman and ceo des moinesderace l schafferdirector annapolisderace l schafferdirector annapolisderace l schafferdes moinesderace l schafferdirector des moinesderace l schaffervice chairman and ceo des moineswayne a schellhammerirvingnicholas j simon iiibostonpeter steven stdirector new yorkpeter steven stdirector bostonpeter steven stdirector annapolispeter steven stdirector annapolismichael steinmetzbostonst peter stevenannapolisst peter stevenannapolissybil taskerchief medical officer gaithersburgfuerst thomasannapolisriddle valerieannapolisriddle valerieannapolismorges wayneannapolismorges wayneannapolisharold r wernerprincetonharold r wernerprincetonkurt wheelerbostondavid p wrightpresident and ceo annapolis microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft   charles a reinhart iii  chief financial officer  pacira pharmaceuticals inc  science center drivesuite san diego ca     sylvan wayparsippany nj    about pacira overview management board of directors  products  pipeline exparel® about exparel® partnering depocyte® about depocyte® strategic partnering clinical trials  platform about depofoam® how it works applications partnership opportunities grants  investors  media company overview corporate governance stock information research coverage press releases sec filings legal resolution overview event calendar online investor kit email alerts information request  careers why pacira opportunities overview management board of directors management team charles a reinhart iiichief financial officer in  charles a reinhart iii joined pacira as chief financial officer responsible for overseeing all financial and capital market activities at pacira including accounting financial reporting financial planning and analysis and investor relations prior to joining pacira mr reinhart served as chief financial officer of covis pharmaceuticals inc archimedes pharma ltd and pharmathene inc he has also held senior financial roles at millennium pharmaceuticals inc cephalon inc and several earlystage life sciences companies mr reinhart has successfully built and managed finance organizations within rapidly growing companies responsible for accounting and financial reporting financial planning and analysis tax treasury risk management and procurement he has worked closely with commercial teams to evaluate sales operations monitor product pricing and implement contracting strategies in addition he has significant experience in investor relations corporate development and capital raising he has been integrally involved in equity and debt financing transactions as well as the evaluation acquisition and integration of multiple products and companies mr reinhart earned his bachelor of science degree from lehigh university and his mba from the wharton school of the university of pennsylvania he is also a cpa quick links corporate presentation news exparel about management grants clinical trials legal resolution overview management david stackchief executive officer and chairman kristen williams jdchief administrative officer general counsel and secretary james b jones md pharmdsenior vice president andchief medical officer robert weilandchief commercial officer charles a reinhart iiichief financial officer scott braunstein md chief strategy officer richard scranton md mphchief scientific officer david st peter md fhmvice president advanced solutions and customer care vladimir kharitonov phdvice president research and development raymond kaczmarekvice president commercial manufacturing and supply operations richard kahrvice president human resources contact us legal site map   pacira pharmaceuticals pacira pharmaceuticals appoints charles a reinhart iii as chief financial officer nasdaqpcrx english français register sign in pacira pharmaceuticals appoints charles a reinhart iii as chief financial officer april    et  source pacira pharmaceuticals inc parsippany nj april   globe newswire  pacira pharmaceuticals inc nasdaqpcrx today announced the appointment of charles a reinhart iii to the position of chief financial officer mr reinhart will be responsible for overseeing all financial and capital market activities at pacira including accounting financial reporting financial planning and analysis and investor relations in this position he will succeed former chief financial officer jim scibetta who is currently president and will report to dave stack chief executive officer and chairman mr reinhart will start in this new role effective tuesday may   “we are excited to welcome another key member to our leadership team in order to properly resource our growing pacira brand” said mr stack “charlie brings valuable experience from working at commercial stage biotech and specialty pharmaceutical companies succeeding in roles that both meet and exceed traditional cfo responsibilities—the type of strategic background and expertise that will help support the successful expansion of exparel® bupivacaine liposome injectable suspension and pipeline opportunities” prior to joining pacira mr reinhart served as chief financial officer of covis pharmaceuticals inc archimedes pharma ltd and pharmathene inc he has also held senior financial roles at millennium pharmaceuticals inc cephalon inc and several early stage life sciences companies mr reinhart has successfully built and managed finance organizations within rapidly growing companies responsible for accounting and financial reporting financial planning and analysis tax treasury risk management and procurement he has worked closely with commercial teams to evaluate sales operations monitor product pricing and implement contracting strategies in addition he has significant experience in investor relations corporate development and capital raising he has been integrally involved in equity and debt financing transactions as well as the evaluation acquisition and integration of multiple products and companies mr reinhart earned his bachelor of science degree from lehigh university and his mba from the wharton school of the university of pennsylvania he is also a cpa “i am pleased to join pacira during this period of investment and growth and look forward to leading the talented finance team that jim scibetta has already assembled here” said mr reinhart “by providing an effective nonopioid option like exparel for the treatment of postsurgical pain pacira has been able to demonstrate improved patient outcomes and lower overall costs to the healthcare system i am excited to build upon the success of this product as well as the company’s future opportunities in my shared commitment with pacira to enhance the patient experience and drive shareholder value” about pacira                                                                            pacira pharmaceuticals inc nasdaqpcrx is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients the company’s flagship product exparel® bupivacaine liposome injectable suspension indicated for singledose infiltration into the surgical site to produce postsurgical analgesia was commercially launched in the united states in april  exparel and two other products have successfully utilized depofoam® a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure and releases them over a desired period of time additional information about pacira is available at wwwpaciracom about exparel® exparel bupivacaine liposome injectable suspension is currently indicated for singledose infiltration into the surgical site to produce postsurgical analgesia the product combines bupivacaine with depofoam® a proven product delivery technology that delivers medication over a desired time period exparel represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri or postsurgical setting by utilizing the depofoam platform a single dose of exparel delivers bupivacaine over time providing significant reductions in cumulative pain score with up to a  percent decrease in opioid consumption the clinical benefit of the opioid reduction was not demonstrated additional information is available at wwwexparelcom    forward looking statements any statements in this press release about our future expectations plans outlook and prospects and other statements containing the words “believes” “anticipates” “plans” “estimates” “expects” “intends” “may” and similar expressions constitute forwardlooking statements within the meaning of the private securities litigation reform act of  actual results may differ materially from those indicated by such forwardlooking statements as a result of various important factors including risks relating to the success of our sales and manufacturing efforts in support of the commercialization of exparel the rate and degree of market acceptance of exparel the size and growth of the potential markets for exparel and our ability to serve those markets our plans to expand the use of exparel to additional indications and opportunities and the timing and success of any related clinical trials the related timing and success of united states food and drug administration supplemental new drug applications the outcome of the us department of justice inquiry our plans to evaluate develop and pursue additional depofoambased product candidates clinical studies in support of an existing or potential depofoambased product our plans to continue to manufacture and provide support services for our commercial partners who have licensed depocyte our commercialization and marketing capabilities our and patheon uk limited’s ability to successfully and timely construct dedicated exparel manufacturing suites and other factors discussed in the “risk factors” of our most recent annual report on form k for the fiscal year ended december   and in other filings that we periodically make with the sec in addition the forwardlooking statements included in this press release represent our views as of the date of this press release important factors could cause our actual results to differ materially from those indicated or implied by forwardlooking statements and as such we anticipate that subsequent events and developments will cause our views to change however while we may elect to update these forwardlooking statements at some point in the future we specifically disclaim any obligation to do so these forwardlooking statements should not be relied upon as representing our views as of any date subsequent to the date of this press releasecompany contact pacira pharmaceuticals inc jessica cho   jessicachopaciracom media contact coyne public relations alyssa schneider   aschneidercoyneprcom related articles other press releases by pacira pharmaceuticals inc pacira announces publication of phase  study of exparel in patients undergoing total knee replacement in the journal of arthroplasty july    pacira pharmaceuticals announces timing for second quarter  financial results webcast and conference call july    pacira announces topline phase  results for exparel® as a singledose nerve block july    pacira pharmaceuticals appoints mark i froimson md to board of directors june    pacira pharmaceuticals to present at the jmp securities life sciences conference june     other news releases in directors and officers in the last  days profile pacira pharmaceuticals inc   subscribe via rss  subscribe via atom  javascript parsippany new jersey united states contact data company contact pacira pharmaceuticals inc jessica cho   jessicachopaciracom media contact coyne public relations alyssa schneider   aschneidercoyneprcom contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here media files pacira pharmaceuticals inc logo logo url  copy the link below formats available original medium small newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved